Key Developments: Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

12:17pm EDT
Change (% chg)

$-1.09 (-1.59%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Baxter International Inc completes CE mark approval for HOMECHOICE CLARIA Automated Peritoneal Dialysis System with SHARESOURCE
8:00am EDT 

Baxter International Inc:Announced completion of CE marking (market approval) in Europe for HOMECHOICE CLARIA, an automated peritoneal dialysis (APD) system integrated with the SHARESOURCE web-based connectivity platform.Says the APD system is designed with user-friendly features and secure two-way connectivity so healthcare providers can have increased visibility to monitor their patients' home peritoneal dialysis (PD) treatments and adjust prescriptions as necessary.PD is a therapy option performed primarily at home by end-stage renal disease patients.  Full Article

Baxter International Inc expands access to healthcare through collaborations
Monday, 30 Mar 2015 09:00am EDT 

Baxter International Inc:Says public-private collaboration with Singapore's Changi General Hospital to meet growing demand for compounded sterile products and received recognition for organizational excellence, inclusion and diversity and corporate social responsibility efforts.Baxter and Changi General Hospital to establish Centre of Excellence in compounding sciences to develop a new model of care delivery that extends beyond the hospital into the community and a patient's home.Says Centre, planned for launch in 2017 on Changi General Hospital premises.  Full Article

Baxter International Inc announces positive phase III results for BAX 817, investigational recombinant treatment for hemophila A and B patients with inhibitors
Friday, 13 Mar 2015 09:00am EDT 

Baxter International Inc:Says positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an investigational recombinant factor VIIa (rFVIIa) treatment for people with hemophilia A or B who develop inhibitors.Prospective, open-label, randomized, multicenter trial was designed to assess the safety and efficacy of BAX 817 in male patients ages 12 to 65 with hemophilia A or B with inhibitors over 6-month period using on-demand therapy.Says trial met its primary endpoint of successful resolution of acute bleeding episodes at 12 hours with both on-demand treatment regimens, dosing either 3x90 µg/kg or 1x270 µg/kg, with an overall success rate of 92 percent (98 percent and 85 percent in each dosing group, respectively).Further, 89 percent of patients in the trial achieved sustained bleeding control for all acute bleeding episodes 24 hours after infusion.  Full Article

Baxter International Inc's BioScience Business acquires Biopharmaceutical Company SuppreMol
Wednesday, 4 Mar 2015 09:00am EST 

Baxter International Inc And SuppreMol GmbH:Says that Baxter has acquired SuppreMol for 200 mln Euros (about $225 mln) before working capital and other adjustments.Acquisition includes SuppreMol's early-stage development portfolio of novel biologic immunoregulatory therapeutics for the treatment of autoimmune diseases, focusing on the modulation of Fc receptor signaling pathways, an immune target that could have broad applications in autoimmune disorders.In addition to portfolio, Baxter also acquires and will continue to operate SuppreMol's operations in Munich.  Full Article

Baxter declares quarterly dividend
Tuesday, 17 Feb 2015 09:00am EST 

Baxter International Inc:Declared a quarterly dividend of $0.52 per Baxter common share.The dividend is payable on April 1, to shareholders of record as of March 11.  Full Article

Baxter International Inc provides progress update on Gene Therapy Program
Thursday, 12 Feb 2015 04:30pm EST 

Baxter International Inc:Provides an update on its gene therapy program, including progress on the Phase I/II open-label clinical trial assessing the safety and optimal dosing level of BAX 335, an investigational factor IX (FIX) gene therapy treatment for hemophilia B.Trial is assessing the safety of ascending doses of BAX 335 to determine the optimal single dose in up to 16 adult patients with hemophilia B at treatment centers in the United States.Primary endpoint is the safety of a single dose of BAX 335 administered intravenously.Secondary endpoints include evaluation of the optimal dose to achieve stable therapeutic plasma FIX activity, as well as pharmacokinetics and immune response to treatment.  Full Article

Baxter International Inc presents additional data from pivotal study of BAX 855, extended half-life investigational recombinant FVIII based on ADVATE for Hemophilia
Wednesday, 11 Feb 2015 09:00am EST 

Baxter International Inc:Presented additional efficacy and safety data from the Phase III pivotal study of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII)treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].New data expand on the previously disclosed topline results from the pivotal trial, which found that BAX 855 met the study`s primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis.Patients in the twice-weekly prophylaxis arm of the trial experienced a 95 percent reduction in median annualized bleed rate (ABR) as compared to those in the on-demand arm (1.9 vs. 41.5, respectively).Says study findings supported Baxter`s Dec. 2014 submission for approval of BAX 855 to the United States Food and Drug Administration (FDA).  Full Article

Baxter International Inc gives Q1 2015 guidance; EPS guidance below analysts' estimates
Thursday, 29 Jan 2015 07:00am EST 

Baxter International Inc:Expects Q1 2015 sales growth of about 2 to 3 pct, excluding the impact of foreign currency.Including the impact of foreign currency, expects Q1 2015 sales to decline about 3 to 4 pct.Expects Q1 2015 earnings from continuing operations, before special items, of $0.85 to $0.90 per diluted share.Q1 2015 earnings guidance excludes about $0.09 per diluted share of projected intangible amortization expense.Reconciling for the inclusion of intangible asset amortization results in GAAP earnings of $0.76 to $0.81 per diluted share, before other special items, for Q1 2015.Q1 2015 revenue of $3.715 bln and EPS of $1.03 - Thomson Reuters I/B/E/S.  Full Article

Baxter International Inc to divest Vero Cell
Monday, 15 Dec 2014 09:00am EST 

Baxter International Inc:Entered into a definitive agreement to sell its Vero cell technology and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics Inc.Financial details were not disclosed.  Full Article

Baxter International Inc announces filing of Form 10 registration statement in connection with planned Spin off of Biopharmaceuticals Business
Wednesday, 10 Dec 2014 05:15pm EST 

Baxter International Inc:Says the filing of an initial Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC) in connection with the company's previously announced plan to spin off its biopharmaceutical business.Filing is an important step in creating two premier global healthcare companies: Baxter International Inc., which will focus on lifesaving medical products; and Baxalta Incorporated, which will focus on developing and marketing innovative biopharmaceuticals.Form 10 filing outlines Baxter's intent to spin off at least 80 percent of the outstanding common stock of Baxalta through a tax-free distribution to Baxter shareholders, with Baxter retaining the remaining shares.The retained equity stake by Baxter of up to 20 percent of Baxalta's shares provides additional flexibility in the capital structures of the two new companies and enhanced value for shareholders.Baxter plans to dispose of the Baxalta common stock in a disciplined manner over a period of time not to exceed five years.  Full Article

Fitch Maintains Baxter International on Rating Watch Negative

(The following statement was released by the rating agency) CHICAGO, March 20 (Fitch) Fitch Ratings has maintained Baxter International Inc.'s (Baxter; NYSE: BAX) long- and short-term ratings on Rating Watch Negative. Fitch placed the company's ratings on Negative Watch in March 2014 when Baxter announced it plans to spin off its BioScience business. A full list of the company's ratings follows at the end of this press release. The ratings apply to approximately $9.21 billion of debt outsta

Search Stocks